NICE clears use of GSK's Jemperli in endometrial cancer

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli vi

FDA approves under-pressure GSK's Jemperli for endometrial c...

The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer. 

Merck gets confirmatory trial win for Keytruda in endometria...

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial. 

Merck, Eisai get triple approvals for Keytruda/Lenvima combi...